Amid daily updates from the pharmaceuticals industry on the latest clinical trials, last week’s announcement by Hutchison China MediTech that it had enrolled patients for a study of colorectal cancer was hardly cause for excitement.
But it represented another step forward for one of several experimental medicines that the company – backed by Li Ka-shing, Asia’s richest man – is developing in China.
With a market capitalisation of just ￡550m, London-listed China MediTech – known as Chi-Med – is not going to shake up “big pharma” overnight. However, it is part of a growing Chinese life science sector that the authorities in Beijing hope will become a force in drug development.
您已閱讀12%（681字），剩余88%（4840字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。